Redant, fair comments and I can see where you are coming from but I have reservations about the current strategy. IMO proceeding with the Phase 2 vax trials now will place undue pressure on the financial stability of the company and more than likely result in another CR this year. Put simply with the current cash burn of $10m in the last 6 months the company does not have enough cash to fund operations and vax trials. A CR will result in a lower SP and dilution which is not in the interests of shareholders. The company should be partnering now at Phase 1 with the big pharma paying all Phase 2,3 and FDA submission costs.
- Forums
- ASX - By Stock
- AVR
- Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-70
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.48 |
Change
-0.020(0.17%) |
Mkt cap ! $233.8M |
Open | High | Low | Value | Volume |
$11.50 | $11.50 | $10.91 | $152.9K | 13.84K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 257 | $11.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.50 | 4416 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 257 | 11.100 |
1 | 631 | 11.000 |
1 | 150 | 10.920 |
1 | 46 | 10.910 |
1 | 48 | 10.900 |
Price($) | Vol. | No. |
---|---|---|
11.480 | 135 | 1 |
11.500 | 4416 | 1 |
11.830 | 500 | 1 |
11.850 | 164 | 1 |
11.900 | 1000 | 1 |
Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online